Navigation Links
Doyle Raizner Pradaxa Case Chosen for Bellwether Early Trial Consideration

(PRWEB) July 30, 2013

As progress continues in the Pradaxa multi district litigation (MDL), the bellwether case selection process has concluded with one of Doyle Raizner’s cases being chosen. Doyle Raizner’s case is one of 16 cases out of approximately 871 currently pending cases that were selected to move into the bellwether case-specific discovery phase. After the conclusion of case-specific discovery, Presiding Judge David Herndon will select four of the 16 cases to proceed to trial on August 11, 2014, November 3, 2014, January 5, 2015, and February 16, 2015. Judge Herndon’s selection of the four trial cases will occur on or before November 22, 2013.

Bellwether case selection is a judicial procedure where a select group of cases are presented for determining core issues, such as liability and damages, for the remaining cases. The outcome of the bellwether trials typically assists in the resolution of all cases within multi-district litigation. They also assist in expediting the trial process. In the case of Pradaxa litigation Judge Herndon promised an expedited process due to the age of the plaintiffs, among other factors.

“The patient whose case was selected for the bellwether selection suffered a near fatal episode of gastrointestinal bleeding just two weeks after her initial dose of Pradaxa,” said Patrick Dennis, the Doyle Raizner partner who manages the firm’s pharmaceutical docket.

Pradaxa litigation was consolidated into a MDL in August 2012 in the Southern District of Illinois, a federal court. [Docket No. 3:13-cv-50028-DRH-SCW] The court will handle claims that the blood thinner, Pradaxa, has serious and often deadly adverse side effects, including an increased risk of gastrointestinal and other bleeds, which were not properly communicated by Boehringer Ingelheim to healthcare professionals or patients. The drug is often prescribed to elderly patients to reduce the risk of stroke in people with atrial fibrillation. Compounding, a possible internal bleeding risk is the lack of an antidote to stop Pradaxa’s internal bleeding side effect. No antidote exists because Pradaxa was rushed to market before Boehringer Ingelheim took efforts to develop an antidote to protect patients taking this drug. As a result, many takers of Pradaxa have suffered from hemorrhages and deaths. The large number of complaints and impending personal injury cases against Pradaxa moved it to the top of 2011’s most dangerous drug report issued by the Institute for Safe Medication Practices, January 12, 2012.

To learn more about the firm and their part in Pradaxa litigation, please visit

About Doyle Raizner LLP:

Doyle Raizner LLP is a national personal injury litigation firm with main offices in Houston, Texas and Phoenix, Arizona. The firm's attorneys specialize in helping victims’ secure fair compensation for injuries or the death of a loved one.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Bleeding Litigation
2. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
3. Pradaxa Lawsuit Attorneys at Wright & Schulte LLC Report on Scheduling of Bellwether Trials in Federal Pradaxa Bleeding Lawsuits
4. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes New Study Linking Pradaxa to Increased Heart Attack Risk
5. New Lawsuit on Pradaxa Bleeding: Now, AttorneyOne Can Provide Advice
6. New Study Casts Doubt on FDA Pradaxa Conclusions
7. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Side Effects Litigation
8. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Pradaxa Bleeding Claims Pending in Federal Litigation Now Exceed 1,000
9. Latest Pradaxa Internal Bleeding Problem Allegation Lawsuits Update; Resource4thePeople Reports Judge Schedules Important Hearing
10. New Lawsuit on Alleged Pradaxa Wrongful Death: Now, AttorneyOne Can Provide Advice
11. Pradaxa Lawsuits Move Ahead As Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: